An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE) Blinatumomab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Blinatumomab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Sponsors Amgen
- 31 May 2019 Results of pooled analysis assessing durability of complete response by using data from two phase II studies published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
- 09 Nov 2016 Status changed from active, no longer recruiting to completed.
- 12 May 2016 Results (pooled analysis of this and other five studies) assessing PK and PD of blinatumomab published in the Clinical Pharmacokinetics.